🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Congrats to Greg Roloff for his co first author publication in Blood Advances on use of brexu-cel in patients with R/R B-ALL and CNS involvement! ashpublications.org/bloodadvances/…

check out results in @BloodJournal for revumenib in R/R NPM1m AML featuring Dr Michael Thirman as co-author! ashpublications.org/blood/article/…

New work featuring Dr Michael Drazer as co-author focused on ANKRD26-RT with increased blasts! ashpublications.org/blood/article/…

Our own Wendy Stock has been named an OncLive.com Giant of Cancer Care - incredibly well deserved! onclive.com/view/giants-of…

more new work featuring Michael Drazer as co-author! This paper in Leukemia Journal looks at deleterious CHEK2 germline variants pubmed.ncbi.nlm.nih.gov/40335619/

Congratulations to our fantastic faculty who were named Exceptional Women in Medicine by Castle Connolly Top Doctors for 2025!!! Incredibly well-deserved by all!! UChicagoCancerCenter UChicago Medicine

Kudos to Anand Patel for his senior author publication in British Journal of Haematology focused on the impact of TP52 mutations on MPN outcomes! pubmed.ncbi.nlm.nih.gov/40400334/

new work in Blood Journal featuring Caner Saygin, MD as co-author looking at type 2 CALR mutations and BCL-xL in MPNs! pubmed.ncbi.nlm.nih.gov/40403318/

Check out this study led by Anand Patel Toyosi Odenike Michael Drazer investigating the LSD1 inhibitor iadademstat combined with ASTX727 in accelerated/blast-phase MPNs! clinicaltrials.gov/study/NCT06661…

We are honored to congratulate Wendy Stock of UChicagoCancerCenter for her 2025 Giants of Cancer Care Leukemia induction! #GiantsCC25 #leusm

We are proud of our fellows who are recipients of this year's Conquer Cancer grants/awards. Congratulations to Dr. Alexandra Rojek, Dr. Daniel Peiffer, Dr. Joseph Cannova, and Dr. Wenji Guo for their ASCO YIAs. Congrats to Dr. Faith Abodunrin on the ASCO merit award! #ASCO25

At #ASCO25, Hamed Rahmani Youshanlouei, MD, presents data that suggests novel agents like inotuzumab, blinatumomab & venetoclax may significantly improve response & relapse-free survival compared to standard chemo in Ph-B-ALL patients. Caner Saygin, MD Wendy Stock University of Chicago Hematology/Oncology

Congratulations to our fellows Alexandra Rojek, Joseph Cannova, Dan Peiffer, and their wonderful mentors on their ASCO YIAs. Thank you Conquer Cancer, the ASCO Foundation ASCO for supporting the career development of our fellows. University of Chicago Hematology/Oncology #ASCO25

paper in @BloodJournal featuring Wendy Stock looking at ALL sensitivity to inotuzumab! pubmed.ncbi.nlm.nih.gov/40435412/

props to Michael Drazer for leading this paper focused on video education in germline testing! pubmed.ncbi.nlm.nih.gov/40472277/

congrats to Wendy Stock & Toyosi Odenike who are co-authors on the Journal of Clinical Oncology publication focusing on the BEAT AML cohort of patients treated with Aza + Ven + Revumenib! ascopubs.org/doi/10.1200/JC…

new research led by Rafael Madero Marroquín Anand Patel and featuring several UChicago Leukemia Program program members that reports using of additional venetoclax-containing regimens in pts prev treated w HMA+VEN dx.doi.org/10.1002/jha2.7…

Check out long-term CALGB10403 data presented by Wendy Stock!

CONGRESS | #EHA2025 | POSTER Wendy Stock Wendy Stock The University of Chicago shares outcomes from a pooled analysis of three studies in pts with B-ALL receiving inotuzumab ozogamicin (InO) stratified by BMI. Efficacy and safety outcomes were broadly consistent across BMI groups for pts with

new publication featuring Toyosi Odenike as a co-author focused on efficacy of decitabine-cedazuridine in patients with CMML! pubmed.ncbi.nlm.nih.gov/40524338/